|
|
News Breaks | | | | February 11, 2013 | | 09:29 EDT |  | RPRX | Repros updates Adroxal study, requests end of Proellex Phase 2 study
Repros Therapeutics provided an update for both of its core clinical programs. As part of the FDA requirement for total number of subjects to be exposed for six months, the company is conducting a 500 subject open label study. To date, the company has enrolled 499 subjects and expects the study to be fully enrolled this week. The company has sent a "request for guidance" letter to the FDA. The key points were the identification of a single high enrolling site with a population whose baseline characteristics appear different from the other sites; the company has proposed enrolling an additional 40 subjects into each of the two pivotal studies to allow for subset analysis while retaining the power of the original protocols; the company proposed moving two sites from the enrolling study ZA-302 to the closed for enrollment study ZA-301. When the company receives guidance from FDA, it will update the financial community. The company has requested an end of Phase 2 meeting for its vaginal Proellex program for the treatment of uterine fibroids. The request was for a meeting before the end of April. | |
|
News For RPRX From The Last 14 Days Check below for free stories on RPRX the last two weeks. |
|
|
| June 19, 2013 | | 19:38 EDT |  | RPRX | Repros Therapeutics 3.75M share Secondary priced at $19.00
 Subscribe for More Information | | | 11:33 EDT |  | RPRX | Stocks with call strike movement; BBRY RPRX
Subscribe for More Information | | | June 17, 2013 | | 16:02 EDT | | RPRX | Repros Therapeutics commences offering of 3M shares of common stock
Subscribe for More Information | | | 14:21 EDT | | RPRX | Repros Therapeutics amends PHS patent license agreement
In a regulatory filing, Repros Therapeutics disclosed that on June 14, Repros entered into the Ninth Amendment to the PHS Patent License Agreement dated April 16, 1999, by and between the National Institutes of Health, the Centers for Disease Control or the Food and Drug Administration, collectively, the Public Health Service or PHS, agencies of the United States Public Health Service within the Department of Health and Human Services and the company.The Ninth Amendment substitutes and amends the development benchmarks that the company is required to meet under the Agreement. The company is also filing herewith the Eighth Amendment to the Agreement dated April 20, 2010, which added additional molecules licensed to the Company from PHS under the Agreement. | | | June 12, 2013 | | 11:32 EDT | | RPRX | Options with decreasing implied volatility: TIVO LAMR FRAN RPRX NAV
| |
|
|
|
|
|
|
